CEL-SCI (CEL-SCI) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Dividend Payout Ratio?

CEL-SCI's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for CEL-SCI's Dividend Payout Ratio or its related term are showing as below:

CVM's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-28), the Dividend Yield % of CEL-SCI is 0.00%.

CEL-SCI's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

CEL-SCI Dividend Payout Ratio Historical Data

The historical data trend for CEL-SCI's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Dividend Payout Ratio Chart

CEL-SCI Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Dividend Payout Ratio

Get a 7-Day Free Trial

CEL-SCI Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CEL-SCI's Dividend Payout Ratio

For the Biotechnology subindustry, CEL-SCI's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEL-SCI's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Dividend Payout Ratio falls into.

CEL-SCI Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

CEL-SCI's Dividend Payout Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Sep. 2023 )	/	EPS without NRI (A: Sep. 2023 )
	=	0	/	-0.73
	=	N/A

CEL-SCI's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.14
	=	N/A

CEL-SCI (AMEX:CVM) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

CEL-SCI Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI (CEL-SCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

LSRM:Germany LSRM:Germany

Address

8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182

Website

https://www.cel-sci.com

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Executives

Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano	officer: Senior Vice President	8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson	director	245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine	director	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor	officer: Chief Scientific Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten	director, officer: Chief Executive Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman	officer: Sr. Vice President, Research	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep	officer: Sr. Vice President, Operations	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De	director, officer: President
C Richard Kinsolving	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182